Her2 Positive Gastric Cancer Epidemiology Forecast

DelveInsight’s ‘HER2+ Gastric Cancer—Epidemiology Forecast—2030’ report delivers an in-depth understanding of HER2+ Gastric Cancer, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Japan, China, and South Korea.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • China
  • South Korea

Study Period: 2018–2030

HER2+ Gastric Cancer Disease Understanding

Gastric Cancer (GC) originates on the inner lining of stomach walls and then penetrates deeper into the stomach walls as the tumor develops. Several different types of cancer can occur in the stomach. The most common type is called adenocarcinoma. Approximately 90% of gastric cancers are adenocarcinoma.


The identification of human epidermal growth factor receptor-2 (HER2) biomarker overexpression in GC represented a significant step toward unraveling the molecular complexity of this disease.


Gastric cancer is more prevalent in men than women. Men consist of ~60% of the diagnosed cases across 7MM, China, and South Korea. GC is most prevalent in the old population above 45 years of age than in other age groups. In countries with regular cancer screening like Japan and Korea, a majority of cases are diagnosed at an early stage, while in countries without screening programs like the US and EU5, most of the cases are diagnosed at a severe stage.

HER2+ Gastric Cancer Epidemiology

The HER2+ Gastric Cancer epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.


Key Findings

The total incident cases of HER2+ Gastric Cancer patients are increasing in 7MM, China, and South Korea during the study period, i.e., 2018–2030.


The disease epidemiology covered in the report provides historical as well as forecasted HER2+ Gastric Cancer symptoms epidemiology segmented as the Incidence of HER2+ Gastric Cancer, Gender-specific cases of HER2+ Gastric Cancer, Age-specific Cases of HER2+ Gastric Cancer, and Stage-specific cases of HER2+ Gastric Cancer. The report includes the incident scenario of HER2+ Gastric Cancer symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan, China, and South Korea from 2018 to 2030.

Country-wise HER2+ Gastric Cancer Epidemiology

The epidemiology segment also provides the HER2+ Gastric Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, and South Korea.

  • The incident cases of HER2+ Gastric Cancer-associated in 7MM + China + South Korea countries were 170,868 in 2020.
  • As per the estimates, China has the largest incident population of HER2+ Gastric Cancer.
  • Among the EU5 countries, Germany had the highest incident cases of HER2+ Gastric Cancer, followed by Italy. On the other hand, the United Kingdom had the lowest incident cases with 1,550 cases in 2020.

Scope of the Report

  • The HER2+ Gastric Cancer report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
  • The HER2+ Gastric Cancer Epidemiology Report and Model provide an overview of HER2+ Gastric Cancer’s risk factors and global trends in the nine major markets (US, France, Germany, Italy, Spain, UK, Japan, China, and South Korea).
  • The report provides insight into HER2+ Gastric Cancer’s historical and forecasted patient pool in nine major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, China, and South Korea.
  • The report helps recognize the growth opportunities in the 7MM + China + South Korea concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of HER2+ Gastric Cancer.
  • The report provides the segmentation of the HER2+ Gastric Cancer epidemiology by the incidence of HER2+ Gastric Cancer in 7MM + China + South Korea.
  • The report provides the HER2+ Gastric Cancer epidemiology segmentation by Gender-specific cases of HER2+ Gastric Cancer in 7MM + China + South Korea.
  • The report provides the HER2+ Gastric Cancer epidemiology segmentation by Age-specific Cases of HER2+ Gastric Cancer in 7MM + China + South Korea.
  • The report provides the HER2+ Gastric Cancer epidemiology segmentation by Stage-specific cases of HER2+ Gastric Cancer in 7MM + China + South Korea.

Report Highlights

  • 10-year Forecast of HER2+ Gastric Cancer epidemiology
  • 7MM + China + South Korea Coverage
  • Incidence of HER2+ Gastric Cancer
  • Gender-specific cases of HER2+ Gastric Cancer
  • Age-specific Cases of HER2+ Gastric Cancer
  • Stage-specific cases of HER2+ Gastric Cancer

KOL Views

We interview KOLs, and SMEs’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM + China + South Korea for the patient population about HER2+ Gastric Cancer?
  • What are the key findings of the HER2+ Gastric Cancer epidemiology across 7MM + China + South Korea, and which country will have the highest number of patients during the forecast period (2018–2030)?
  • What would be the total number of HER2+ Gastric Cancer patients across the 7MM + China + South Korea during the forecast period (2018–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018–2030)?
  • At what CAGR the patient population is expected to grow in 7MM + China + South Korea during the forecast period (2018–2030)?
  • What are the disease risk, burden, and unmet needs of HER2+ Gastric Cancer?
  • What are the currently available treatments for HER2+ Gastric Cancer?

Reasons to buy

The HER2+ Gastric Cancer epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global HER2+ Gastric Cancer market.
  • Quantify patient populations in the global HER2+ Gastric Cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HER2+ Gastric Cancer therapeutics in each of the markets covered.
  • Understand the magnitude of the HER2+ Gastric Cancer population by its incidence.
  • Understand the magnitude of the HER2+ Gastric Cancer population by its Gender-specific cases.
  • Understand the magnitude of the HER2+ Gastric Cancer population by its Age-specific cases.
  • Understand the magnitude of the HER2+ Gastric Cancer population by its Stage-specific cases.
  • The HER2+ Gastric Cancer epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The HER2+ Gastric Cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. HER2+ Gastric Cancer Market Overview at a Glance

3.1. Market Share (%) Distribution of HER2+ Gastric Cancer in 2018

3.2. Market Share (%) Distribution of HER2+ Gastric Cancer in 2030

4. Executive Summary of HER2+ Gastric Cancer

5. Disease Background and Overview

5.1. Introduction

5.2. HER2 expression and correlation with pathologic variables

5.3. Concordance between HER2 Overexpression and Gene Amplification

5.4. Clinical Manifestations

5.5. Risk factors

5.6. Pathogenesis

5.7. Stages of Gastric Cancer

5.8. Diagnosis

5.8.1. Diagnosis Guidelines

5.9. Treatment

5.9.1. Treatment guidelines

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM, China, and South Korea Total Incident Population of HER2+ Gastric Cancer

6.3. Epidemiology of HER2+ Gastric Cancer

6.4. The United States

6.4.1. Incident Cases of HER2+ Gastric Cancer in the United States

6.4.2. Gender-specific cases of HER2+ Gastric Cancer in the United States

6.4.3. Age-specific Cases of HER2+ Gastric Cancer in the United States

6.4.4. Stage-specific cases of HER2+ Gastric Cancer in the United States

6.5. EU5

6.5.1. Germany

6.5.2. France

6.5.3. Italy

6.5.4. Spain

6.5.5. The United Kingdom

6.6. Japan

6.6.1. Incident Cases of HER2+ Gastric Cancer in Japan

6.6.2. Gender-specific cases of HER2+ Gastric Cancer in Japan

6.6.3. Age-specific Cases of HER2+ Gastric Cancer in Japan

6.6.4. Stage-specific cases of HER2+ Gastric Cancer in Japan

6.7. China

6.7.1. Incident Cases of HER2+ Gastric Cancer in China

6.7.2. Gender-specific cases of HER2+ Gastric Cancer in China

6.7.3. Age-specific Cases of HER2+ Gastric Cancer in China

6.7.4. Stage-specific cases of HER2+ Gastric Cancer in China

6.8. South Korea

6.8.1. Incident Cases of HER2+ Gastric Cancer in South Korea

6.8.2. Gender-specific cases of HER2+ Gastric Cancer in South Korea

6.8.3. Age-specific Cases of HER2+ Gastric Cancer in South Korea

6.8.4. Stage-specific cases of HER2+ Gastric Cancer in South Korea

7. KOL Views

8. Appendix

8.1. Bibliography

8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Table

Table 1: Summary of HER2+ Gastric Cancer, Market, Epidemiology, and Key Events (2018–2030)

Table 2: CAP-ASCP-ASCO HER2 Testing and Clinical Decision-making in Gastroesophageal Adenocarcinoma Guidelines, 2019

Table 3: Total Incident Population of HER2+ Gastric Cancer in 7MM, China, and South Korea (2018–2030)

Table 4: Incident Cases of HER2+ Gastric Cancer in the United States (2018–2030)

Table 5: Gender-specific cases of HER2+ Gastric Cancer in the United States (2018–2030)

Table 6: Age-specific Cases of HER2+ Gastric Cancer in the United States (2018–2030)

Table 7: Stage-specific cases of HER2+ Gastric Cancer in the United States (2018–2030)

Table 8: Incident Cases of HER2+ Gastric Cancer in Germany (2018–2030)

Table 9: Gender-specific cases of HER2+ Gastric Cancer in Germany (2018–2030)

Table 10: Age-specific Cases of HER2+ Gastric Cancer in Germany (2018–2030)

Table 11: Stage-specific cases of HER2+ Gastric Cancer in Germany (2018–2030)

Table 12: Incident Cases of HER2+ Gastric Cancer in France (2018–2030)

Table 13: Gender-specific cases of HER2+ Gastric Cancer in France (2018–2030)

Table 14: Age-specific Cases of HER2+ Gastric Cancer in France (2018–2030)

Table 15: Stage-specific cases of HER2+ Gastric Cancer in France (2018–2030)

Table 16: Incident Cases of HER2+ Gastric Cancer in Italy (2018–2030)

Table 17: Gender-specific cases of HER2+ Gastric Cancer in Italy (2018–2030)

Table 18: Age-specific Cases of HER2+ Gastric Cancer in Italy (2018–2030)

Table 19: Stage-specific cases of HER2+ Gastric Cancer in Italy (2018–2030)

Table 20: Incident Cases of HER2+ Gastric Cancer in Spain (2018–2030)

Table 21: Gender-specific cases of HER2+ Gastric Cancer in Spain (2018–2030)

Table 22: Age-specific Cases of HER2+ Gastric Cancer in Spain (2018–2030)

Table 23: Stage-specific cases of HER2+ Gastric Cancer in Spain (2018–2030)

Table 24: Incident Cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Table 25: Gender-specific cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Table 26: Age-specific Cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Table 27: Stage-specific cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Table 28: Incident Cases of HER2+ Gastric Cancer in Japan (2018–2030)

Table 29: Gender-specific cases of HER2+ Gastric Cancer in Japan (2018–2030)

Table 30: Age-specific Cases of HER2+ Gastric Cancer in Japan (2018–2030)

Table 31: Stage-specific cases of HER2+ Gastric Cancer in Japan (2018–2030)

Table 32: Incident Cases of HER2+ Gastric Cancer in China (2018–2030)

Table 33: Gender-specific cases of HER2+ Gastric Cancer in China (2018–2030)

Table 34: Age-specific Cases of HER2+ Gastric Cancer in China (2018–2030)

Table 35: Stage-specific cases of HER2+ Gastric Cancer in China (2018–2030)

Table 36: Incident Cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Table 37: Gender-specific cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Table 38: Age-specific Cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Table 39: Stage-specific cases of HER2+ Gastric Cancer in South Korea (2018–2030)

List of Figures

Figure 1: Manifestations of Gastric Cancer

Figure 2: Risk Factors Involved in Gastric Cancer

Figure 3: Stages of Gastric Cancer

Figure 4: HER2-testing algorithm in adenocarcinoma of the stomach and gastroesophageal junction

Figure 5: Guidelines by Japanese Society of Pathology

Figure 6: Strategies for targeting HER2-positive gastric cancer

Figure 7: Total Incident Population of HER2+ Gastric Cancer in 7MM, China, and South Korea (2018–2030)

Figure 8: Incident Cases of HER2+ Gastric Cancer in the United States (2018–2030)

Figure 9: Gender-specific cases of HER2+ Gastric Cancer in the United States (2018–2030)

Figure 10: Age-specific Cases of HER2+ Gastric Cancer in the United States (2018–2030)

Figure 11: Stage-specific cases of HER2+ Gastric Cancer in the United States (2018–2030)

Figure 12: Incident Cases of HER2+ Gastric Cancer in Germany (2018–2030)

Figure 13: Gender-specific cases of HER2+ Gastric Cancer in Germany (2018–2030)

Figure 14: Age-specific Cases of HER2+ Gastric Cancer in Germany (2018–2030)

Figure 15: Stage-specific cases of HER2+ Gastric Cancer in Germany (2018–2030)

Figure 16: Incident Cases of HER2+ Gastric Cancer in France (2018–2030)

Figure 17: Gender-specific cases of HER2+ Gastric Cancer in France (2018–2030)

Figure 18: Age-specific Cases of HER2+ Gastric Cancer in France (2018–2030)

Figure 19: Stage-specific cases of HER2+ Gastric Cancer in France (2018–2030)

Figure 20: Incident Cases of HER2+ Gastric Cancer in Italy (2018–2030)

Figure 21: Gender-specific cases of HER2+ Gastric Cancer in Italy (2018–2030)

Figure 22: Age-specific Cases of HER2+ Gastric Cancer in Italy (2018–2030)

Figure 23: Stage-specific cases of HER2+ Gastric Cancer in Italy (2018–2030)

Figure 24: Incident Cases of HER2+ Gastric Cancer in Spain (2018–2030)

Figure 25: Gender-specific cases of HER2+ Gastric Cancer in Spain (2018–2030)

Figure 26: Age-specific Cases of HER2+ Gastric Cancer in Spain (2018–2030)

Figure 27: Stage-specific cases of HER2+ Gastric Cancer in Spain (2018–2030)

Figure 28: Incident Cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Figure 29: Gender-specific cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Figure 30: Age-specific Cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Figure 31: Stage-specific cases of HER2+ Gastric Cancer in the United Kingdom (2018–2030)

Figure 32: Incident Cases of HER2+ Gastric Cancer in Japan (2018–2030)

Figure 33: Gender-specific cases of HER2+ Gastric Cancer in Japan (2018–2030)

Figure 34: Age-specific Cases of HER2+ Gastric Cancer in Japan (2018–2030)

Figure 35: Stage-specific cases of HER2+ Gastric Cancer in Japan (2018–2030)

Figure 36: Incident Cases of HER2+ Gastric Cancer in China (2018–2030)

Figure 37: Gender-specific cases of HER2+ Gastric Cancer in China (2018–2030)

Figure 38: Age-specific Cases of HER2+ Gastric Cancer in China (2018–2030)

Figure 39: Stage-specific cases of HER2+ Gastric Cancer in China (2018–2030)

Figure 40: Incident Cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Figure 41: Gender-specific cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Figure 42: Age-specific Cases of HER2+ Gastric Cancer in South Korea (2018–2030)

Figure 43: Stage-specific cases of HER2+ Gastric Cancer in South Korea (2018–2030)

  • Tags:
  • HER2+ Gastric Cancer Epidemiology
  • HER2+ Gastric Cancer
  • HER2+ Gastric Cancer Pipeline
  • HER2+ Gastric Cancer Companies
  • HER2+ Gastric Cancer prevalent pop...
  • HER2+ Gastric Cancer incident popu...
  • HER2+ Gastric Cancer patients diag...
  • HER2+ Gastric Cancer treatment alg...

Forward to Friend

Need A Quote